Miruvor
Sign up
The short answer

What studies of elderberry found

1paper on elderberry
37people in 1 study testing elderberry alone
1randomised trial, the strongest kind of study

At a glance, by condition

Long COVID: C Might help, very uncertain

Based on the strongest evidence, the randomised trial (very low certainty): 6 of 9 findings are C.

9 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Elderberry might help some people with long COVID, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 1 paper.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. Elderberry · Long COVID is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Symptoms

Anxiety1 study · 37 people took elderberry Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (74 in all).

The randomised trial74 randomised · 30 days · 1 Capsule (250 mg), twice daily

Anxiety improved more than in the comparison group.

The evidence is very uncertain about the effect of elderberry on anxiety in long COVID. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (74 in all)
See the 1 study
  1. Potential use of Immunodaat® (Botanical extract of Elderberry -Sambucus Nigra L.) in the management of Post Covid-19 symptoms- a comparative, multi-centric, randomized, clinical study (2022) preprint

    People in the study
    74 randomised
    Dose
    1 Capsule (250 mg), twice daily
    Outcome
    Anxiety (number of subjects with symptom)
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    High
    Selection of the reported result
    Low
Cognition (brain fog)1 study · 37 people took elderberry Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (74 in all); effect size 1.45 (large).

The randomised trial74 randomised · 30 days · 1 Capsule (250 mg), twice daily

Cognition (brain fog) improved more than in the comparison group.

The evidence is very uncertain about the effect of elderberry on cognition (brain fog) in long COVID. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (74 in all)
  • Effect size 1.45 (large)

How big was the difference?

1.45, large. The effect size compares elderberry with group b i.e. conventional management (standard of care- vitamins like b complex, vitamin c, zinc supplements or medications as per symptom requirement.).

See the 1 study
  1. Potential use of Immunodaat® (Botanical extract of Elderberry -Sambucus Nigra L.) in the management of Post Covid-19 symptoms- a comparative, multi-centric, randomized, clinical study (2022) preprint

    People in the study
    74 randomised
    Dose
    1 Capsule (250 mg), twice daily
    Outcome
    Lack of concentration VAS (0-100)
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Some concerns
    Measurement of the outcome
    High
    Selection of the reported result
    Low
Fatigue1 study · 37 people took elderberry Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (74 in all); effect size 0.99 (large).

The randomised trial74 randomised · 30 days · 1 Capsule (250 mg), twice daily

Fatigue improved more than in the comparison group.

The evidence is very uncertain about the effect of elderberry on fatigue in long COVID. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (74 in all)
  • Effect size 0.99 (large)

How big was the difference?

0.99, large. The effect size compares elderberry with group b i.e. conventional management (standard of care- vitamins like b complex, vitamin c, zinc supplements or medications as per symptom requirement.).

See the 1 study
  1. Potential use of Immunodaat® (Botanical extract of Elderberry -Sambucus Nigra L.) in the management of Post Covid-19 symptoms- a comparative, multi-centric, randomized, clinical study (2022) preprint

    People in the study
    74 randomised
    Dose
    1 Capsule (250 mg), twice daily
    Outcome
    Fatigue (severity)
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    High
    Selection of the reported result
    Low
Low mood or anxiety1 study · 37 people took elderberry Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (74 in all).

The randomised trial74 randomised · 30 days · 1 Capsule (250 mg), twice daily

Low mood or anxiety improved more than in the comparison group.

The evidence is very uncertain about the effect of elderberry on low mood or anxiety in long COVID. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (74 in all)
See the 1 study
  1. Potential use of Immunodaat® (Botanical extract of Elderberry -Sambucus Nigra L.) in the management of Post Covid-19 symptoms- a comparative, multi-centric, randomized, clinical study (2022) preprint

    People in the study
    74 randomised
    Dose
    1 Capsule (250 mg), twice daily
    Outcome
    Altered mood (number of subjects with symptom)
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    High
    Selection of the reported result
    Low
Sleep1 study · 37 people took elderberry Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (74 in all).

The randomised trial74 randomised · 30 days · 1 Capsule (250 mg), twice daily

Sleep improved more than in the comparison group.

The evidence is very uncertain about the effect of elderberry on sleep in long COVID. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (74 in all)
See the 1 study
  1. Potential use of Immunodaat® (Botanical extract of Elderberry -Sambucus Nigra L.) in the management of Post Covid-19 symptoms- a comparative, multi-centric, randomized, clinical study (2022) preprint

    People in the study
    74 randomised
    Dose
    1 Capsule (250 mg), twice daily
    Outcome
    Insomnia (number of subjects with symptom)
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    High
    Selection of the reported result
    Low
Autonomic symptoms1 study · 37 people took elderberry Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 74 people found no clear difference; a small benefit can't be ruled out.

The randomised trial74 randomised · 30 days · 1 Capsule (250 mg), twice daily

No clear difference in autonomic symptoms.

The evidence is very uncertain about the effect of elderberry on autonomic symptoms in long COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 74 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. Potential use of Immunodaat® (Botanical extract of Elderberry -Sambucus Nigra L.) in the management of Post Covid-19 symptoms- a comparative, multi-centric, randomized, clinical study (2022) preprint

    People in the study
    74 randomised
    Dose
    1 Capsule (250 mg), twice daily
    Outcome
    Palpitation (number of subjects with symptom)
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    High
    Selection of the reported result
    Low
Breathlessness1 study · 37 people took elderberry Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 74 people found no clear difference; a small benefit can't be ruled out.

The randomised trial74 randomised · 30 days · 1 Capsule (250 mg), twice daily

No clear difference in breathlessness.

The evidence is very uncertain about the effect of elderberry on breathlessness in long COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 74 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. Potential use of Immunodaat® (Botanical extract of Elderberry -Sambucus Nigra L.) in the management of Post Covid-19 symptoms- a comparative, multi-centric, randomized, clinical study (2022) preprint

    People in the study
    74 randomised
    Dose
    1 Capsule (250 mg), twice daily
    Outcome
    Dyspnea (number of subjects with symptom)
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    High
    Selection of the reported result
    Low
Pain1 study · 37 people took elderberry Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 74 people found no clear difference; a small benefit can't be ruled out.

The randomised trial74 randomised · 30 days · 1 Capsule (250 mg), twice daily

No clear difference in pain.

The evidence is very uncertain about the effect of elderberry on pain in long COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 74 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. Potential use of Immunodaat® (Botanical extract of Elderberry -Sambucus Nigra L.) in the management of Post Covid-19 symptoms- a comparative, multi-centric, randomized, clinical study (2022) preprint

    People in the study
    74 randomised
    Dose
    1 Capsule (250 mg), twice daily
    Outcome
    Headache (number of subjects with symptom)
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    High
    Selection of the reported result
    Low

Daily life and health overall

Quality of life1 study · 37 people took elderberry Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (74 in all); effect size 0.58 (moderate).

The randomised trial74 randomised · 30 days · 1 Capsule (250 mg), twice daily

Quality of life improved more than in the comparison group.

The evidence is very uncertain about the effect of elderberry on quality of life in long COVID. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (74 in all)
  • Effect size 0.58 (moderate)

How big was the difference?

0.58, moderate. The effect size compares elderberry with group b i.e. conventional management (standard of care- vitamins like b complex, vitamin c, zinc supplements or medications as per symptom requirement.).

See the 1 study
  1. Potential use of Immunodaat® (Botanical extract of Elderberry -Sambucus Nigra L.) in the management of Post Covid-19 symptoms- a comparative, multi-centric, randomized, clinical study (2022) preprint

    People in the study
    74 randomised
    Dose
    1 Capsule (250 mg), twice daily
    Outcome
    Physical Domain WHO-QOL BREF
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    High
    Selection of the reported result
    Low

Side effects

Stopping because of side effects1 study
Side effects studies reported1 kind
Side effects studies reported, and how many studies reported each
Side effectStudies that reported it
Nausea or stomach upset1 study

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    250 mg at the start

  2. 2Top dose

    Most often 250 mg (1 of 1 studies)

Doses across 1 study

250 to 250 mg.

Each study’s dose, as printed

All papers

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime